Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ANVS

DatePrice TargetRatingAnalyst
2/10/2025Buy → Hold
D. Boral Capital
10/25/2024$25.00Hold → Buy
Maxim Group
12/29/2023$36.00Buy
Canaccord Genuity
7/7/2021$45.00 → $150.00Buy
Maxim Group
More analyst ratings

$ANVS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

    MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on March 26, 2025, it received notice (the "Notice") from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholde

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

    MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna. "We are at a pivotal moment in our company's journey as we have entered the late clinical stages for both Alzheimer's and Parkinson's. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications," commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. "A

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

    MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results. In 2024, Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials—Phase 2/3 AD and Phase 3 PD. Both studies yielded promising results, reinforcing buntanetap's ability to improve cognition in AD and PD patients, as well as motor function in PD patients. Building on this

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANVS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ANVS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ANVS
SEC Filings

See more

$ANVS
Leadership Updates

Live Leadership Updates

See more
  • Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

    MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials. "We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development,

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Annovis Bio Appoints Andrew Walsh as Vice President Finance

    BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance.  "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • TheracosBio Announces the Appointments of Jim Greenwood to Board of Directors and Jeff McGroarty as Chief Financial Officer

    TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres

    $ANVS
    $SFE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance/Investors Services
    Finance

$ANVS
Financials

Live finance-specific insights

See more
  • Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease

    Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct

    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ANVS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more